A Phase I Open-label Study to Evaluate the Effect of Multiple Doses of AZD1775 on the Pharmacokinetics of Substrates for CYP3A, CYP2C19, CYP1A2 and to Provide Data on the Effect of AZD1775 on QT Interval in Patients With Advanced Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 26 Mar 2018
At a glance
- Drugs AZD-1775 (Primary) ; Caffeine; Granisetron; Midazolam; Omeprazole
- Indications Solid tumours
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 19 Dec 2017 Planned End Date changed from 18 Jul 2018 to 19 Jul 2018.
- 19 Dec 2017 Planned primary completion date changed from 18 Jul 2018 to 19 Jul 2018.
- 19 Dec 2017 Status changed from not yet recruiting to recruiting.